It has been previously demonstrated that therapeutic inhibition of the prostaglandin E2 (PGE2)-degrading enzyme, 15-prostaglandin dehydrogenase (15-PGDH), was able to improve muscle strength in aged mice. Researchers from Epirium Bio Inc. have now reported the discovery and preclinical characterization an orally bioavailable small molecule inhibitor of 15-PGDH – MF-300 – being developed for the treatment of neuromuscular dysfunction.

Additional early-stage research and drug discovery news in brief, from: Tenaya Therapeutics.

Zomagen Biosciences Ltd. has prepared and tested new NLRP3 inflammasome modulators reported to be useful for the treatment of autoimmune diseases, cardiovascular disorders, inflammatory disorders, liver diseases, lung diseases, metabolic diseases and neurological disorders.

University of California Oakland and University of Copenhagen scientists have jointly developed calcium/calmodulin-dependent protein kinase type II subunit α (CaMK2A) modulators reported to be useful for the treatment of brain injury, narcolepsy, Angelman syndrome, Down syndrome and stroke.

Research at Prelude Therapeutics Inc. has led to the identification of thaizole-pyrimdiine cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.

A recent Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. patent describes nitrogen-containing heterocyclic derivatives acting as EGFR (del19 mutant) inhibitors and reported to be useful for the treatment of non-small-cell lung cancer.